HIV drugs News and Research

RSS

Early treatment of HIV makes infection transmission less likely: Study

“It's a game-changer,” Michel Sidibe, executive director of UNAIDS, said. “I am completely amazed.” It was noted that anti-HIV drugs called antiretroviral drugs can suppress HIV in an infected patient and also help to prevent its spread through intercourse, he said. He predicted a rethink of the strategies that have evolved since the first cases of AIDS were recorded in June 1981. “The implications are multiple,” said Mr Sidibe. “However, money will be the major challenge.”

15 May 2011

Antiretroviral therapy can reduce risk of HIV transmission in couples

When one partner in a couple is infected with HIV and the other is not, treatment with antiretroviral drugs can dramatically lower the chances of the infected partner passing along the disease to his or her mate, a new evidence review finds.

12 May 2011

HIV drugs can be used to target malaria and other parasitic diseases

Drugs used to treat HIV may form templates for lifesaving drugs targeted at malaria and other parasitic diseases, according to a new study from Cardiff University.

10 May 2011

Study measures cost-effectiveness of trauma drug published in PLoS One

How much would you pay for an extra year of healthy life? The cost of filling up your car at the petrol pumps? Researchers at the London School of Hygiene & Tropical Medicine have found that a year of life could be saved for around the price of filling up the tank of an average family car in the UK - which is a fitting comparison bearing in mind that most of the patients who will benefit from this cheap life-saving drug have been hit by cars.

4 May 2011

HIV drugs may also combat parasitic diseases: Study

Scientists have discovered that drugs used to treat HIV may also one day become lifesaving drugs targeted at parasitic diseases such as leishmaniasis and malaria.

3 May 2011

MSF letter criticizes Johnson & Johnson for not joining Medicines Patent Pool

Medecins Sans Frontieres recently sent a letter to Johnson & Johnson criticizing the pharmaceutical company for "refusing to make patents on three HIV drugs available to a program that would reduce the cost of the medicines in developing countries," the Star-Ledger reports.

27 Apr 2011

Study questions suitability of anti-retroviral drugs for the young

According to a new major study one in eight children born with HIV becomes resistant to the three main classes of drugs used to suppress the virus within five years of starting treatment. This is the first major study that looks at drug resistance in 1,000 European children born with HIV. It raises questions about the suitability of anti-retroviral drugs for the young.

25 Apr 2011

Gilead's increase of HIV drugs price unreasonable, says AHF

Today AIDS Healthcare Foundation (AHF), the largest global AIDS organization, blasted the news that Gilead Sciences Inc. increased the prices of several of its top selling products at the beginning of the month. The California-based drug maker increased the price of its biggest seller, HIV treatment Atripla, by 5.1%. Gilead also raised the price of HIV drugs Truvada and Emtriva by 7.9%.

5 Apr 2011

Scientists engineer new protein that prevents HIV virus entry into cells

In what could be a potential breakthrough in the battle against AIDS and a major development in the rational design of new drugs, scientists have engineered a new protein that prevents the virus from entering cells.

1 Apr 2011

HIV uses base excision repair pathway to insert DNA into host-cell genome

The human immunodeficiency virus (HIV), the cause of AIDS, makes use of the base excision repair pathway when inserting its DNA into the host-cell genome, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Crippling the repair pathway prevents the virus from completing this critical step in the retrovirus's life cycle.

25 Mar 2011

Kenya’s condom shortage

Health authorities in Kenya have revealed that the country was facing a condom shortage and it has made an emergency order of 45 million more. A January consignment of 19 million condoms lasted for around six weeks.

23 Mar 2011

New research may shed light on how HIV virus reactivates from latency

New research enhances the current knowledge of how human immunodeficiency virus type-1, which causes AIDS, controls the cell cycle of cells that it infects. The new findings may shed light on how the virus reactivates after entering a dormant state, called latency.

28 Feb 2011

Antiepileptic drugs could make HIV drugs less effective

A Michigan State University researcher is looking to uncover the risks of treating seizures in HIV-positive patients, providing much-needed data on possible interactions between antiepileptic drugs and antiretroviral medicines that potentially could make HIV drugs less effective or the disease itself drug resistant.

23 Feb 2011

Research findings reveal HIV's hiding spot, new way to stop the virus

HIV adapts in a surprising way to survive and thrive in its hiding spot within the human immune system, scientists have learned. While the finding helps explain why HIV remains such a formidable foe after three decades of research - more than 30 million people worldwide are infected with HIV - it also offers scientists a new, unexpected way to try to stop the virus.

24 Jan 2011

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism.

20 Jan 2011

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

Two multinational clinical studies indicate that the RDI’s system for predicting how HIV and AIDS patients will respond to different drugs could be a useful tool with potential clinical and economic benefits. The studies, published in the January issue of AIDS Patient Care and STDs, involved highly experienced physicians in the USA, Canada and Italy who used the system to help them select the optimum combination of HIV drugs for patients whose therapy was failing.

18 Jan 2011

Indian government rejects Abbott's patent application for second-line ARV

India's patent office "has rejected American drug maker Abbott Laboratories' patent application for an HIV combination drug, allowing low-cost local drug makers to make and sell their generic versions in India and other countries where the medicine is not patented," Economic Times reports (1/4).

5 Jan 2011

U.S., South Africa sign PEPFAR partnership agreement

Secretary of State Hillary Rodham Clinton and South African International Relations and Cooperation Minister Maite Nkoana-Mashabane on Tuesday signed a "partnership agreement that will guide efforts on fighting HIV/AIDS in the African nation," Bloomberg BusinessWeek reports (Wessels, 12/15).

17 Dec 2010

European Commission must stop attacking generic medicines, says ITPC

On International Human Rights Day, as the European Commission (EC) and the Government of India meet in Brussels to finalise a European Union (EU)-India free trade agreement, the International Treatment Preparedness Coalition (ITPC) calls on Indian negotiators to put the right to health of its citizens and of the fifteen million HIV-positive people worldwide needing treatment above the pharmaceutical companies' interests and profits.

8 Dec 2010

New cell-based assay for reliable testing of HIV inhibitors

EASY-HIT is a new cell-based assay system for simple and reliable testing of HIV inhibitors. This system was developed under the leadership of Professor Ruth Brack-Werner at the Institute of Virology.

2 Dec 2010